Anti-CD38
Bristol-Myers Squibb’s Abecma Becomes First Approved CAR T-Cell Therapy for Multiple Myeloma in Japan
2022-01-24
LATEST
EVENT
2023-06-05
Redefining Early Stage Investments (RESI) 2023 conference series – RESI Boston
Boston, USA